



**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 7, 2008**

**QUESTCOR PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**California**  
(State or Other Jurisdiction  
of Incorporation)

**001-14758**  
(Commission File Number)

**33-0476164**  
(I.R.S. Employer  
Identification No.)

**3260 Whipple Road Union City, California**  
(Address of Principal Executive Offices)

**94587**  
(Zip Code)

Registrant's telephone number, including area code: **(510) 400-0700**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## **TABLE OF CONTENTS**

[Item 8.01 Other Events.](#)  
[SIGNATURES](#)

---

## [Table of Contents](#)

### **Item 8.01 Other Events.**

On November 6 and 7, 2008, Don Bailey, the President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. (the "Company") since May 2007, completed the exercise and same-day sale of 341,661 options to purchase shares of common stock of the Company at prices ranging from \$8.50 to \$8.75 per share. Mr. Bailey exercised these options for portfolio diversification purposes. After completion of the exercises and same-day sales, Mr. Bailey's combined position in both shares of common stock of the Company and options to purchase shares of common stock of the Company totaled approximately one million shares and options.

---

[Table of Contents](#)

**SIGNATURES**

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2008

QUESTCOR PHARMACEUTICALS, INC.

By: /s/ Gary M. Sawka  
Gary M. Sawka  
Senior Vice President of Finance, and  
Chief Financial Officer